HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients

Soo Youn Bae, Yoon La Choi, Sangmin Kim, Minkuk Kim, Jiyoung Kim, Seung Pil Jung, Min Young Choi, Se Kyung Lee, Won Ho Kil, Jeong Eon Lee, Seok Jin Nam

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Breast cancer is a highly heterogeneous malignancy. The triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2) breast cancer subtypes are highly aggressive and are associated with a poor prognosis. The therapeutic targets for TNBC remain undefined, and many patients with the HER2 subtype acquire resistance to therapy after prolonged treatment. The objective of this study was to evaluate the prognostic significance of HER3 expression in invasive breast carcinoma. We established matched tissue microarray (TMA) blocks and clinical data from 950 cases of invasive breast carcinoma with long-term clinical follow-up data (median 109.7 months). Using the TMAs, we characterized the expression of ER, PR, HER2, EGFR, and HER3 by immunohistochemistry. Each case was classified as one of four IHC-based subtypes based on the expression of hormonal receptor (HR) and HER2. The clinicopathological characteristics and survival of 950 patients were analyzed by subtype. In the TNBC subtype, the HER3(+) group showed poorer disease-free survival (DFS, P = 0.010) and overall survival (OS, P = 0.015) than the HER3(-) group. In the HER2 subtype, the HER3(+) group also showed poorer DFS (P = 0.022) and OS (P = 0.077) than the HER3(-) group. However, there was no difference in patients with HR-positive breast cancer. HER3 expression was associated with poor DFS in both the TNBC and HER2 subtypes and poor OS in the TNBC subtype. HER3 overexpression is an important prognostic marker in hormone receptor-negative breast cancer, and further study is needed to clarify the role of HER-3 targeted treatment.

Original languageEnglish
Pages (from-to)741-750
Number of pages10
JournalBreast Cancer Research and Treatment
Volume139
Issue number3
DOIs
Publication statusPublished - 2013 Jun 1

Fingerprint

Triple Negative Breast Neoplasms
Immunohistochemistry
Hormones
Breast Neoplasms
Survival
Therapeutics
Disease-Free Survival
human ERBB2 protein
Neoplasms

Keywords

  • Breast cancer
  • HER2
  • HER3
  • Hormone receptor
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. / Bae, Soo Youn; La Choi, Yoon; Kim, Sangmin; Kim, Minkuk; Kim, Jiyoung; Jung, Seung Pil; Choi, Min Young; Lee, Se Kyung; Kil, Won Ho; Lee, Jeong Eon; Nam, Seok Jin.

In: Breast Cancer Research and Treatment, Vol. 139, No. 3, 01.06.2013, p. 741-750.

Research output: Contribution to journalArticle

Bae, Soo Youn ; La Choi, Yoon ; Kim, Sangmin ; Kim, Minkuk ; Kim, Jiyoung ; Jung, Seung Pil ; Choi, Min Young ; Lee, Se Kyung ; Kil, Won Ho ; Lee, Jeong Eon ; Nam, Seok Jin. / HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. In: Breast Cancer Research and Treatment. 2013 ; Vol. 139, No. 3. pp. 741-750.
@article{d378dc91b1834a729adc1bddaf8418d3,
title = "HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients",
abstract = "Breast cancer is a highly heterogeneous malignancy. The triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2) breast cancer subtypes are highly aggressive and are associated with a poor prognosis. The therapeutic targets for TNBC remain undefined, and many patients with the HER2 subtype acquire resistance to therapy after prolonged treatment. The objective of this study was to evaluate the prognostic significance of HER3 expression in invasive breast carcinoma. We established matched tissue microarray (TMA) blocks and clinical data from 950 cases of invasive breast carcinoma with long-term clinical follow-up data (median 109.7 months). Using the TMAs, we characterized the expression of ER, PR, HER2, EGFR, and HER3 by immunohistochemistry. Each case was classified as one of four IHC-based subtypes based on the expression of hormonal receptor (HR) and HER2. The clinicopathological characteristics and survival of 950 patients were analyzed by subtype. In the TNBC subtype, the HER3(+) group showed poorer disease-free survival (DFS, P = 0.010) and overall survival (OS, P = 0.015) than the HER3(-) group. In the HER2 subtype, the HER3(+) group also showed poorer DFS (P = 0.022) and OS (P = 0.077) than the HER3(-) group. However, there was no difference in patients with HR-positive breast cancer. HER3 expression was associated with poor DFS in both the TNBC and HER2 subtypes and poor OS in the TNBC subtype. HER3 overexpression is an important prognostic marker in hormone receptor-negative breast cancer, and further study is needed to clarify the role of HER-3 targeted treatment.",
keywords = "Breast cancer, HER2, HER3, Hormone receptor, Prognosis",
author = "Bae, {Soo Youn} and {La Choi}, Yoon and Sangmin Kim and Minkuk Kim and Jiyoung Kim and Jung, {Seung Pil} and Choi, {Min Young} and Lee, {Se Kyung} and Kil, {Won Ho} and Lee, {Jeong Eon} and Nam, {Seok Jin}",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s10549-013-2570-6",
language = "English",
volume = "139",
pages = "741--750",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients

AU - Bae, Soo Youn

AU - La Choi, Yoon

AU - Kim, Sangmin

AU - Kim, Minkuk

AU - Kim, Jiyoung

AU - Jung, Seung Pil

AU - Choi, Min Young

AU - Lee, Se Kyung

AU - Kil, Won Ho

AU - Lee, Jeong Eon

AU - Nam, Seok Jin

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Breast cancer is a highly heterogeneous malignancy. The triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2) breast cancer subtypes are highly aggressive and are associated with a poor prognosis. The therapeutic targets for TNBC remain undefined, and many patients with the HER2 subtype acquire resistance to therapy after prolonged treatment. The objective of this study was to evaluate the prognostic significance of HER3 expression in invasive breast carcinoma. We established matched tissue microarray (TMA) blocks and clinical data from 950 cases of invasive breast carcinoma with long-term clinical follow-up data (median 109.7 months). Using the TMAs, we characterized the expression of ER, PR, HER2, EGFR, and HER3 by immunohistochemistry. Each case was classified as one of four IHC-based subtypes based on the expression of hormonal receptor (HR) and HER2. The clinicopathological characteristics and survival of 950 patients were analyzed by subtype. In the TNBC subtype, the HER3(+) group showed poorer disease-free survival (DFS, P = 0.010) and overall survival (OS, P = 0.015) than the HER3(-) group. In the HER2 subtype, the HER3(+) group also showed poorer DFS (P = 0.022) and OS (P = 0.077) than the HER3(-) group. However, there was no difference in patients with HR-positive breast cancer. HER3 expression was associated with poor DFS in both the TNBC and HER2 subtypes and poor OS in the TNBC subtype. HER3 overexpression is an important prognostic marker in hormone receptor-negative breast cancer, and further study is needed to clarify the role of HER-3 targeted treatment.

AB - Breast cancer is a highly heterogeneous malignancy. The triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2) breast cancer subtypes are highly aggressive and are associated with a poor prognosis. The therapeutic targets for TNBC remain undefined, and many patients with the HER2 subtype acquire resistance to therapy after prolonged treatment. The objective of this study was to evaluate the prognostic significance of HER3 expression in invasive breast carcinoma. We established matched tissue microarray (TMA) blocks and clinical data from 950 cases of invasive breast carcinoma with long-term clinical follow-up data (median 109.7 months). Using the TMAs, we characterized the expression of ER, PR, HER2, EGFR, and HER3 by immunohistochemistry. Each case was classified as one of four IHC-based subtypes based on the expression of hormonal receptor (HR) and HER2. The clinicopathological characteristics and survival of 950 patients were analyzed by subtype. In the TNBC subtype, the HER3(+) group showed poorer disease-free survival (DFS, P = 0.010) and overall survival (OS, P = 0.015) than the HER3(-) group. In the HER2 subtype, the HER3(+) group also showed poorer DFS (P = 0.022) and OS (P = 0.077) than the HER3(-) group. However, there was no difference in patients with HR-positive breast cancer. HER3 expression was associated with poor DFS in both the TNBC and HER2 subtypes and poor OS in the TNBC subtype. HER3 overexpression is an important prognostic marker in hormone receptor-negative breast cancer, and further study is needed to clarify the role of HER-3 targeted treatment.

KW - Breast cancer

KW - HER2

KW - HER3

KW - Hormone receptor

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84879766749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879766749&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2570-6

DO - 10.1007/s10549-013-2570-6

M3 - Article

C2 - 23722313

AN - SCOPUS:84879766749

VL - 139

SP - 741

EP - 750

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -